© Copyright 2006 FICDART, Inc.

all Patients Pending on all FICDART products!



PLEASE CONSIDER THAT SUBOXONE MAY VERY WELL BE THE MOST DANGEROUS DRUG THAT HAS EVER BEEN APPROVED BY OUR GOVERNMENT.
IF YOU WANT TRUE AND ACCURTE INFOMATION ON SUBOXONE PLEASE READ THE FOLLOWING. IT IS AN INFORMATIVE DOCUMENT THAT EXPLORES THE TRUE NATURE AND DANGERS OF SUBOXONE AND SUBUTEX. PLEASE READ FOR YOUR OWN SAFETY. IT IS COMPLEX BUT I HAVE TRIED TO EDIT IT AS TO MAKE IT ACCESSIBLE TO EVERYONE. IF YOU WANT TO BE RIDE OF YOUR ADDICTION THEN GET OFF THE DRUGS. SWAPPING ONE ADDITION FOR ANOTHER IS JUST PLAIN STUPID AND THE FACILITIES OUT THERE THAT ARE DOING THIS ARE OUT FOR ONE THING AND ONE THING ONLY, YOUR MONEY. DON'T FALL INTO THEIR TRAP.

SUBOXONE AND SUBUTEX: THE DANGERS AND PITFALLS


Each section of discussion of this drug will also have the reference used, gathered at the end. I have also comment at the bottom of some sections.

HISTORY

The first thing to understand is a little history of the medication.Buprenorphine which is four parts of the medication suboxone. It is a semi-synthetic opiate with partial agonist and antagonist action. Buprenorphine hydrochloride was first marketed in the 1980s by Reckitt & Colman as an analgesic available generally as Temgesic 0.2 mg sublingual tablets, and as Buprenex in a 0.3 mg/ml injectable formulation. In October 2002, the Food and Drug Administration additionally approved Suboxone and Subutex, Buprenorphine's high-dose sublingual pill preparations for opioid addiction, and as such the drug is now also used for this purpose. In the European Union, Suboxone and Subutex, were approved for opioid addiction treatment in September 2006. In the Netherlands, Buprenorphine is a List II drug of the Opium Law, though special rules and guidelines apply to its prescription and dispensation. In the USA, it has been a Schedule III drug under the United Nations Convention on Psychotropic Substances since it was rescheduled from Schedule V just before FDA approval of Suboxone and Subutex. In the recent years, Buprenorphine has been introduced in most European countries as a transdermal formulation for the treatment of chronic pain.
What is misleading about this information is it never mention the other ligand that is in Suboxone, “Naloxone”, however if you read on in this document it does mention that Suboxone contains the opioid antagonist Naloxone to deter the abuse of the tablets by intravenous injection. A good analogy to this would be like putting rat poison in cigarettes to deter people from smoking. It is pure inanity and very bad medicine even by Western standards but most addiction practitioners using Suboxone just do not see it this way.

A BIT OF REALITY

Following is information about a death due to an overdose from Suboxone. '“The recent Suboxone-related deaths of two Milwaukee-area residents has drawn negative attention to federal rules that allow patients to use the buprenorphine-based drug at home, the Milwaukee-Wisconsin journal Sentinel reported April 2, 2009. Some local officials blame wider availability of the drug for increasing the risk of abuse by recreational users. Milwaukee police said they saw evidence of illicit trafficking of Suboxone even before it was linked to the overdose deaths of these two teenage students. Chuck Wood of the Waukesha County Sheriff's Department said informants noted that a street market for the drug has developed because recreational users have found a way to use Suboxone to get high. Suboxone was specifically designed to limit abuse potential by including the opiate antagonist Naloxone in the formulation. It was going to be so controlled, Wood said. Now we're seeing it out in the community. An official with the federal Substance Abuse & Mental Health Services Administration (SAMHSA) said the overdose deaths seem to be the tragic results of abuse rather than any inherent danger in Suboxone. Suboxone is a very safe drug, said Robert Lubran, SAMHSA's director of pharmacologic therapies. There's a reason why they're controlled substances -- because they're abusable. It really does its job well, said Jim Aker, a counselor at ProHealth Care, a program in Waukesha that has used Suboxone to treat 140 recovering addicts during the past two years. Police believe that the two overdose deaths were the result of ingesting Suboxone along with other substances; some users incorrectly believe that Suboxone mitigates the effects of other drugs. Tim Baxter, medical director of Reckitt Benckiser Pharmaceuticals Inc., said Suboxone alone cannot trigger a fatal overdose. But he said it has been linked to 15 deaths nationally when combined with alcohol or other drugs. Baxter said abuse has been tapering off, as drug users discover Suboxone's limited potential for intoxication. Some kids will decide, Oh, this sounds like fun, we'll have a go, Baxter said. They may try it once, but they go on to something else."

The above article was taken from this internet site,

There is an enormous amount of fabrication and misinformation within this article and the standard of keeping the public misinformed continues. First off Suboxone does only one thing for the addicted person, move them from one addition to another. I would like to ask Robert Lubran how many of the addicts that they think are recovered are actually completely off narcotics since Suboxone is a narcotic. The other thing is the inaccuracy about its mitigation qualities. It will mitigate other narcotic preparation since Naloxone is a pure antagonist and Buprenorphine partially agonizes and antagonizes its effect on different allesteric receptors. Also remember that since both Buprenorphine and Naloxone come from the same part of the poppy, “thebaine”, their will be withdrawal symptoms from both drugs when you try to stop taking Suboxone. Read further on and you will understand.

THE WAISMANN METHOD

Buprenorphine offers some advantages over methadone, a common replacement therapy for opiate addiction. Buprenorphine is longer-lasting so patients may not have to take it as often as methadone and buprenorphine offers patients the convenience of a at home supply, whereas those on methadone must report daily to a clinic to receive their dose. Opiate replacement or maintenance therapy may be helpful for many in the withdrawal phase of treatment to help patients ease off of opiates. The problem is its potential for abuse and dependence, which may require a second detox. Swapping one addiction for another is not the answer. There is safe, medically-supervised treatments for opiate addiction, including those drugs used in replacement therapy. Opiate-free treatment programs are ideal for those who wish to become completely independent from narcotic medications.

Buprenorphine detox performed with the Waismann Method a medical procedure under anesthesia that induce and speed the withdrawal while the patient sleeps. Buprenorphine addiction is a serious problem in the United States and tends to happen quickly and to unsuspecting individuals who have been prescribed Buprenorphine for legitimate pain reasons. The addiction creeps up quickly and once you have a Buprenorphine addiction, chances are it's too late to find an easy solution to get off Buprenorphine. The Buprenorphine detox treatment is performed in a full service hospital under the strict supervision of one of our medical directors. You are followed every step of the way from admission to release, and are assisted in creating a plan for remaining opiate-free once you complete your Buprenorphine detox.

The above information was taken from the internet site,

It must be said that not everyone is a proponent of this method of detox but it is far better then most other methods that sometimes include more opiate use. Those facilities that use any method that includes more narcotic use are extending the addiction. There is only one true method that will release you from narcotic addiction. Stop taking narcotics, period. It must be done safely and supervised especilly for the hopelessly addicted. It must always be stressed that the hope of being free of the addiction must always be the, "Prise For The Effort", "The Light at the End of the Tunnel" and "The Hope For a Better Day". However the inherent risked involved with the abuse or use of Suboxone is seldom discussed in any articles or reference books that can be researched. Only when the clinician takes an unbias look at the drug do you ever hear some of the inherient risks. It is never discussed by any individual physicians involved in treating addicts with Suboxone. According to these individuals Suboxone is a wonder drug. Please read on as the true dangers of this drug isI approach.

PHARMACOLOGY AND PHARMACOKINETICS

Buprenorphine is a “thebaine" derivative with powerful analgesia approximately twenty-five to forty times as potent as morphine. Thebaine (paramorphine) is an opiate alkaloid. A minor constituent of opium, thebaine is chemically similar to both morphine and codeine, but has stimulatory rather than depressant effects, causing strychnine-like convulsions at higher doses. Strychnine is a very toxic, colorless crystalline alkaloid used as a pesticide, particularly for killing small vertebrates such as birds and rodents. Strychnine causes muscular convulsions and eventually death through asphyxia or sheer exhaustion. Strychnine is only being used as a comparison to the ultimate effect of paramorphine at higher doses. Thebaine is not used therapeutically, but can be converted industrially into a variety of compounds including oxycodone, oxymorphone, nalbuphine, naloxone, naltrexone buprenorphine and etrophine. Buprenorphine’s analgesic effect is due to partial agonist activity at μ-opioid receptors, i.e., when the molecule binds to a receptor, it is less likely to transduce a response in contrast to a full agonist such as morphine. An agonist versus an antagonist is a drug that alters the activity of a receptor, narcotic receptors in this case, throughout the nervous system. Buprenorphine also has very high binding affinity for the receptor such that opioid receptor antagonist like naloxone only partially reverse its effects. Biochemical receptors are large protein molecules that can be activated by the binding of a hormone or drug also chemically referred to as a ligand. Receptors can be membrane-bound, occurring on the cell membrane of cells, or intracellular, such as on the nucleus or mitochondrion. Binding occurs as a result of noncovalent interaction between the receptor and its ligand, at locations called the binding site on the receptor. A receptor may contain one or more binding sites for different ligands. Binding to the active site on the receptor regulates receptor activation directly. The activity of receptors can also be regulated by the binding of a ligand to other sites on the receptor, as in allosteric binding sites. Antagonists mediate their effects through receptor interactions by preventing agonist-induced responses. This may be accomplished by binding to the active site or the allosteric site. In addition, antagonists may interact at unique binding sites not normally involved in the biological regulation of the receptor's activity to exert their effects. These two properties must be carefully considered by the practitioner, as an overdose cannot be easily reversed. An important note is overdose is unlikely in addicted patients or people with tolerance to opioids who use the drug sublingually as meant in the case of Subutex/Suboxone, especially if there are no benzodiazepines involved. Person with seizure disorder present a particularly difficulty since a benzodiazepine may be necessary for seizure control. Persons with seizure disorders should never be put on Suboxone regardless of their past opiate use. Another approach should be used. Use in persons physically dependant on full-agonist opioids may trigger full opioid withdrawal that also cannot be easily reversed and can last over twenty-four hours, as the drug's mean half-life is thirty-seven hours. This will mean that if the antagonist finds it way to the receptor without the benefit of Buprenorphine also binding to the receptor an addict will go into deadly precipitated withdrawal. Buprenorphine is also a k-opioid receptor antagonist, and partial/full agonist at the recombinant human ORL1 nociceptin receptor also known as the NOP receptor. Buprenorphine hydrochloride is administered by intramuscular injection, intravenous infusion, via a transdermal patch, as a sublingual tablet or an ethanolic liquid oral solution. It is not administered orally, due to very high first-pass metabolism. Buprenorphine is metabolized by the liver, via the CYP3A4 isozyme of the cytochrome P450 enzyme system, into norbuprenorphine by N-dealkylation, glucuronidation and other metabolites. The metabolites are further conjugated with glucuronic acid and eliminated mainly through excretion into the bile. The elimination half-life of buprenorphine is 20–73 hours (mean 37). Due to the mainly hepatic elimination there is no risk of accumulation in patients with renal impairment and in the elderly. However, individuals with hepatic disease or hepatic issues should never be put on Buprenorphine or Naloxone products due to hepatic impact. The main active metabolite, norbuprenorphine, is a δ-opioid receptor and ORL1 receptor agonist and μ- and κ-opioid receptor partial agonist. However, buprenorphine antagonizes its effects at the κ-opioid receptor. Plasma concentrations after application of transdermal buprenorphine increase steadily and the minimum effective therapeutic dose (100 pg/ml) is reached at eleven hours and twenty-one hours for a single 35 and 70 μg/h patch, respectively. Peak plasma concentration (Cmax) is reached in about sixty hours (305 and 624 pg/ml for the 35 and 70 μg/h strength patch, respectively), and is markedly longer than with 0.3 mg intravenous buprenorphine (0.41 hours). Transdermal buprenorphine has a half-life of approximately thirty hours, and a bioavailability of approximately 50%, which is comparable to sublingual buprenorphine.

ABUSE

Buprenorphine is also used recreationally, typically by opioid users and the potential for abuse is much greater than previously considered. Typical effects include analgesia, a sense of euphoria and increased verbal communication. Due to the high potency of tablet forms of buprenorphine, only a small amount of the drug need be ingested to achieve the desired effects. The buprenorphine preparation, Suboxone, comes in an orange lemon-lime flavored tablet for sublingual administration. The taste of Suboxone is described by some to be very unpleasant. Possible explanations for this unpleasant taste could be the bitter taste of the buprenorphine itself, or that fact that it acts as a deterrent to abuse and was done intentionally by the pharmaceutical company, Reckitt Benckiser. Buprenorphine abuse is very common in Scandinavia, especially in Finland and Sweden. In 2007, the authorities in Uppsala county in Sweden confiscated more buprenorphine than cocaine, ecstasy and GHB. In Finland, somewhere between 2005-2006, illegal use of Subutex (commonly intravenously) has preceded the large number of amphetamine usage. Intravenous administration of dissolved Subutex pills and insufflations of pulverized pills are the most common ways of recreational buprenorphine use.

A HIDDEN DANGER AND ANOTHER DETOX

Since there is very little written about what is being suggested here, support for any conclusion is difficult at best to find. Since the pharmacology of buprenorphine states that the first-pass action of the liver will remove such a large percentage of the ligand Buprenorphine. then another approach was needed to get the opioid into the system. So sublingually was considered and developed but due to the overwhelming presser to have this drug controlled both from a drug classification as well as having Naloxone joined along side the Buprenorphine to prevent abuse. This is what then becomes the problem. Should someone swallow this pill instead of keeping it under their tongue to dissolve they may be slammed into the worst precipitated withdrawal symptoms imaginable. Typically the potential for seizures, heart stoppage, breathing difficulties and many other issues may be realized. Since it is also true that the patient must be fully half life depleted of their current narcotic and in the throws of withdrawl before the Suboxone can be administered it seems idiotic to put them right back on another narcotic. You will enevitably need another detox from the Suboxone and this addictions will probably the hardest of all to beat. There is a lot of different information being passed on the internet about Suboxone. It is being said that Suboxone works by, "Closing the door halfway and will help ease the addicted individual off the drug addiction". Or it has also been stated that the Suboxone is used to help allow the addict to, "Straighten up their lives by having their addiction controlled and off street drugs". Do not listen to this psyco bable because Subosone is for one thing and one thing only, "To perpetuate your addiction and keep you coming back to spend more money on detox". Find a facility that is all about getting free of the addiction. Their out there you just have to be willing to look real hard, ask a lot of questions and learn a lot about your addiction.

A FINAL OPINION

Note that the article taken from the Milwaukee- Wisconsin journal Sentinel never mentions whether or not these 140 recovering addicts have ever gotten off Suboxone. Everyone seems to think that this drug is the golden gateway to opiate addiction and getting off narcotics, this simply is NOT true. What needs to be statistically gathered is how many addicts are now off the Suboxone after being treated with it. Since almost all addicts are sent on there way still on Suboxone the success of Suboxone is never really statistically gather since true success mean getting off narcotics entirely. The statistics being gathered refering to a, “Successful Course of Treatment ”, refers only to getting an addict onto Suboxone. There are no statistics as of yet as to how many actually are getting completely off narcotics. This statistic, the true statistic, will be much lower than what treatment facilities are currently expressing. Also notice that in this article they never mention that the other drugs they are referring to are not other narcotic preparations since the antagonist, Naloxone does its job by repelling all other forms of narcotics. However, it will only be a short time before a young street chemist finds a way to remove the Naloxone to leave only the Buprenorphine, unless this has already been achieved. After this occurs then Suboxone may become the most abuse narcotic substance known and it will quickly rival methadone for the number of deaths. Suboxone is a drug that should have never been approved by the FDA. It is a big money market for treatment facilities and pharmacies throughout the world. Before long the entire world is going to be addicted to Buprenorphine in one form or another it is just a matter of time. New compounds are being tested for use everyday. Right now they are looking into a anti-depressant uses for this drug. Suboxone will not get an addict off narcotics it only switched them from one narcotic addiction to another. However, due to the still powerful effects of euphoria, as well as other addictive quantities within Suboxone, since it is entirely of thebaine, it will be more difficult to overcome this addiction then what most addicts were on. Another approach should be considered and if you have a Liver difficulty in any form this drug should not be used. If there is a history of seizures this drug should not be used. The fact is there are so many contraindication for this drug it basically should never be used for anything. Remember the commercial that refers to your brain on drug and then they fry an egg to further demonstrate the concern. Well just replace drugs for Suboxone and this is an accurate picture for anyone that goes on this drug. There will be a very good chance they will never get off it alive. Since this document attempts to provide complete and thorough information about Suboxone and Subutex there is only one real conclusion, "SUBOXONE IS A POISON AND IS DEADLY TO EVERYONE THAT TAKES IT".

1. Not nearly enough information is being provided before individuals are being put on Buprenorphine products.

2. The death toll from this drug may yet rival any other drug in use today.

3. If you truly want off drugs then get off them, don’t just switch your habits to yet another drug.

4. If you have seizures or Liver issues DO NOT GO ON THIS PRODUCT. It could mean quick death for your Liver or an impossibility to get off. Since you are not suppose to use benzodiazepines individuals with seizure concerns could be quickly put in a life threatening situation. Benzodiazepines are drugs uses to often treat Epilepsy. There is yet very little statistical information on these facts.

5. If you have started using Suboxone then try to get help from the others that are on this drug. Go to the chat rooms and see what others are saying about this drug. There may be something there that can help. Bottom line do not try to detox on your own since it very well could kill you.

DO NOT GO ON SUBOXONE OR SUBUTEX. YOU MAY NEVER GET OFF THEM ALIVE.

Please remember this was only my educated opinion if you are considering treatment with this drug for addiction get educated before you do.

This document was constructed from a great deal of research done by the author but inevitable it is still the opinion of the author. It is based on over 200 hours of research as well as the authors own experience with Suboxone.


Dr. Julian R. Gothican

CREDENTIALS: PhD; Computer Science and Physics, Graduate Degree; Sociology, Theology, Degrees; Mathematics and Pharmacology

REFERANCE

1. List of psychotropic Substance under international control.

2. Mendelson J, Jones RT, Fernandez I, Welm S, Melby AK, Baggott MJ. Buprenorphine and naloxone interactions in opiate-dependent volunteers. Clin Pharmacol Ther. 1996 Jul;60(1):105-14.

3. Fudala PJ, Yu E, Macfadden W, Boardman C, Chiang CN. Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts. Drug Alcohol Depend. 1998 Mar 1;50(1):1-8.

4. Stoller KB, Bigelow GE, Walsh SL, Strain EC. Abstract Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacology (Berl). 2001 Mar;154(3):230-42.

5. Strain EC, Preston KL, Liebson IA, Bigelow GE. Abstract Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers. J Pharmacol Exp Ther. 1992 Jun;261(3):985-93.

6. Harris DS, Jones RT, Welm S, Upton RA, Lin E, Mendelson J. Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine. Drug Alcohol Depend. 2000 Dec 22;61(1):85-94.

7. Strain EC, Stoller K, Walsh SL, Bigelow GE. Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers. Psychopharmacology (Berl). 2000 Mar;148(4):374-83.

8. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) 40. Laura McNicholas. US Department of Health and Human Services.

9. Transtec Summary of Product Characteristics

10. Napp Pharmaceuticals

11. Reckitt Benckiser Buprenorphine Bibliography

12. Huang P. et al. (2001): "Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist", J. Pharmacol. Exp. Ther. 297(2):688-95.

13. Bodkin JA. et al. (1995): "Buprenorphine treatment of refractory depression", Journal of Clinical Psychopharmacology 15:49-57. PMID 7714228

14. Drug War Ensnares Doctors, Not Dealers – Oct 2, 2003

15. The War on Drugs Is a War on Doctors by Rep. Ron Paul

16. Suboxone FAQ

17. Budd K, Raffa RB. (edts.) Buprenorphine - The unique opioid analgesic. Thieme 2005 (ISBN 3-13-1342211-0)

18. Van Dorp E. et al. (2006) Naloxone reversal of buprenorphine- induced respiratory depression. Anesthesiology 105 (1): 51-57

19. “Subutex Abuse on the Rise (Swedish)”, Upsala Nya Tidning, 2007-05-06.

20. Hermansson, Gunnar “Subutex Instead of Heroin (Swedish)

21. Buprenorphine: New Medication to Treat Substance Abuse, Matthew Doutherty.

22. R. S. Schottenfeld et al. (1997) Department of Psychiatry, Yale University School of Medicine

23. Rolley Johnson et al., NEJM, 343(18):1290-1297, 2000

24. AJ Giannini. Drugs of Abuse--Second Edition. Los Angeles, Practice Management Information Corporation, 1997.



Click here to Enter







Email- gothicalmaster@gothicaldea.com

Email Request 4 USPO, West Virginia, 99999